

Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis

Toshiki Tsunogai, Toya Ohashi, Yohta Shimada, Takashi Higuchi, Ayaka Kimura, Ayako M. Watabe, Fusao Kato, Hiroyuki Ida, and Hiroshi Kobayashi

Correspondence: tohashi@jikei.ac.jp

<https://doi.org/10.1016/j.omtm.2022.09.004>

(Molecular Therapy: Methods & Clinical Development 25, 448–460; June 2022)

In the originally published version of this article, the following was included as part of the procedure for GFAP analysis in this study: "Cerebral tissues were homogenized in nine volumes of 50 mM Tris-HCl, pH 7.5 (Tris buffer), and protease inhibitor cocktail (PIC; Roche Diagnostics, Indianapolis, IN), followed by sonication and centrifugation at $18,000 \times g$ for 1 h at 4 °C. Residual pellets were lysed with seven volumes of Tris buffer containing 2% sodium dodecyl sulfate (SDS) and PIC, followed by sonication and centrifugation." This is partly incorrect, and the proper procedure is as follows: "Cerebral tissues were homogenized in nine volumes of 50 mM Tris-HCl, pH 7.5 (Tris buffer), and protease inhibitor cocktail (PIC; Roche Diagnostics, Indianapolis, IN), followed by sonication. Sonicated sample is diluted with 10% sodium dodecyl sulfate (SDS) to make final solution of 2% SDS concentration, followed by sonication and centrifugation."

This change has been corrected online, and the authors apologize for this error.

